small molecule

RABEPRAZOLE SODIUM

RABEPRAZOLE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameRABEPRAZOLE SODIUM
Active ingredientRABEPRAZOLE SODIUM
Strength20MG
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2015
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.